TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03479567

Intervention type: OTHER
Group type: OTHER
Intervention: Gait accelerometry
Description: accelerometric assessment of gait (Dynaport Hybrid): 7m walk in 3 conditions (normal pace, fast, double task)

Intervention type: OTHER
Group type: OTHER
Intervention: Gait accelerometry
Description: accelerometric assessment of gait (Dynaport Hybrid): 7m walk in 3 conditions (normal pace, fast, double task)

Intervention type: OTHER
Group type: OTHER
Intervention: Gait accelerometry
Description: accelerometric assessment of gait (Dynaport Hybrid): 7m walk in 3 conditions (normal pace, fast, double task)

Intervention type: OTHER
Group type: OTHER
Intervention: balance accelerometry
Description: accelerometric assessment of balance (Dynaport Hybrid) during 10 seconds trial in 3 conditions (side-by-side, semitandem, tandem)
Study: NCT03500952

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postpartum Birth Control
Description: A 4-page patient information leaflet in portable document format and text format hosted online.
Study: NCT03167411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexagliflozin
Description: Bexagliflozin tablets, 20 mg
Study: NCT03479567

Intervention type: OTHER
Group type: OTHER
Intervention: balance accelerometry
Description: accelerometric assessment of balance (Dynaport Hybrid) during 10 seconds trial in 3 conditions (side-by-side, semitandem, tandem)
Study: NCT00927576

Intervention type: BEHAVIORAL
Intervention: Choice reaction time
Description: Testing the time needed to discriminate and respond to different visual stimuli.

Intervention type: BEHAVIORAL
Intervention: Choice reaction time
Description: Testing the time needed to discriminate and respond to different visual stimuli.
Study: NCT03167411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexagliflozin
Description: Bexagliflozin tablets, 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide Injection
Description: Byetta® (Exenatide), 10 ug, bid, subcutaneous injection
Study: NCT03479567

Intervention type: OTHER
Group type: OTHER
Intervention: balance accelerometry
Description: accelerometric assessment of balance (Dynaport Hybrid) during 10 seconds trial in 3 conditions (side-by-side, semitandem, tandem)

Intervention type: OTHER
Group type: OTHER
Intervention: Fine motor skill test
Description: assessment of fine motor skills with Purdue Pegboard, with dominant hand, non-dominant hand and bimanual
Study: NCT03975608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation of CALM
Description: The therapy is built up by 3-8 sessions (duration about 45-60 min) over a period of 6 months. All dimensions are explored with every patient, but the order and extent of each dimension are adapted to the individual needs of the patient.~The sessions address the 4 dimensions of the original program designed for palliative cancer patients:~1. Symptom management and communication with healthcare providers~2. Changes in self and relations with each others~3. Spirituality, sense of meaning, and purpose~4. Thinking of the future, hope, and mortality~As an adaptation, the investigators will especially focus on two other aspects which take into account the specific symptoms and challenges in patients with ALS: (i) communication skills and (ii) emotional expression and control.
Study: NCT03479567

Intervention type: OTHER
Group type: OTHER
Intervention: Fine motor skill test
Description: assessment of fine motor skills with Purdue Pegboard, with dominant hand, non-dominant hand and bimanual

Intervention type: OTHER
Group type: OTHER
Intervention: Fine motor skill test
Description: assessment of fine motor skills with Purdue Pegboard, with dominant hand, non-dominant hand and bimanual

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Paratonia Assessment Instrument (PAI)
Description: diagnosis of paratonia based on passive movement of the four limbs

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Paratonia Assessment Instrument (PAI)
Description: diagnosis of paratonia based on passive movement of the four limbs
Study: NCT02024815

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam radiotherapy
Description: External Beam radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam radiotherapy
Description: External Beam radiotherapy
Study: NCT01087645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN9925 (oral)
Description: Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels. Progression to next dose will be based on safety evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN9925 (i.v.)
Description: As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels
Study: NCT03479567

Intervention type: OTHER
Group type: OTHER
Intervention: myotonometric measurement of muscle tone
Description: MyotonPRO measurement of muscle tone

Intervention type: OTHER
Group type: OTHER
Intervention: myotonometric measurement of muscle tone
Description: MyotonPRO measurement of muscle tone

Intervention type: OTHER
Group type: OTHER
Intervention: myotonometric measurement of muscle tone
Description: MyotonPRO measurement of muscle tone
Study: NCT03858634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPL-716
Description: A loading dose of KPL-716 720 mg (2x maintenance dose) administered via 2 subcutaneous (SC) injections within 30 minutes on Day 1. All subsequent doses of KPL-716 (360 mg maintenance dose) administered via a single SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dose administered via 2 SC injections within 30 minutes on Day 1. All subsequent doses of placebo administered via a single SC injection.
Study: NCT01087645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN9925 (oral)
Description: Subjects will be randomised to receive a single dose of NN9925 in up to three different concentrations. The dose will be selected based on the results of part 1
Study: NCT00927576

Intervention type: BEHAVIORAL
Intervention: Verbal fluency
Description: Evaluating how many words are produced in 90s.

Intervention type: BEHAVIORAL
Intervention: Verbal fluency
Description: Evaluating how many words are produced in 90s.
Study: NCT01087645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will be randomised to receive a single dose of placebo
Study: NCT03469375

Intervention type: DRUG
Intervention: modified-FOLFIRINOX
Description: LAPC patients with mFOLFIRINOX-based neoadjuvant therapy or not was set as the main intervention
Study: NCT00927576

Intervention type: BEHAVIORAL
Intervention: Verbal list learning
Description: Evaluating short-term memory, learning, and memory interference in the recall of 12-word lists, presented three times. Evaluating long-term memory and recognition after a 20 min interval.

Intervention type: BEHAVIORAL
Intervention: Verbal list learning
Description: Evaluating short-term memory, learning, and memory interference in the recall of 12-word lists, presented three times. Evaluating long-term memory and recognition after a 20 min interval.

Intervention type: BEHAVIORAL
Intervention: Trail making test
Description: Evaluating visuomotor speed and executive function in Trail Making Tests, A and B. In the first, subjects connect successive numbers with the mouse. In the second, they connect numbers and letters in alternation.

Intervention type: BEHAVIORAL
Intervention: Trail making test
Description: Evaluating visuomotor speed and executive function in Trail Making Tests, A and B. In the first, subjects connect successive numbers with the mouse. In the second, they connect numbers and letters in alternation.

Intervention type: BEHAVIORAL
Intervention: Design fluency
Description: Subjects create the maximal number of 4-line patterns in 90 s.

Intervention type: BEHAVIORAL
Intervention: Design fluency
Description: Subjects create the maximal number of 4-line patterns in 90 s.

Intervention type: BEHAVIORAL
Intervention: Questionnaire completion
Description: Question completion time is measured on each question of the Post-Traumatic Stress Disorder check list (PCL) and on the cognitive failures questionnaire.

Intervention type: BEHAVIORAL
Intervention: Questionnaire completion
Description: Question completion time is measured on each question of the Post-Traumatic Stress Disorder check list (PCL) and on the cognitive failures questionnaire.
Study: NCT01307046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0954A
Description: Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Tablet containing losartan potassium (100 mg), once daily
Study: NCT02466035

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG
Description: Extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG
Study: NCT04528550

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mononuclear cells
Description: Intrathecal transplantation of autologous bone marrow-derived mononuclear cells through lumbar injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Included patients will receive the same amount of saline through lumbar injection.
Study: NCT01014572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Aerobic exercise training consisting of exercise of choice (walking, eliptical machine, stairstepper, stationary bike, etc.) 4 times per week for 40 minutes at a base pace, and two higher intensity steady state sessions per month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Aerobic exercise training consisting of exercise of choice (walking, eliptical machine, stairstepper, stationary bike, etc.) 4 times per week for 40 minutes at a base pace, and two higher intensity steady state sessions per month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alagebrium (generic: ALT-711)
Description: The dosage of our drug, ALT-711, will be one 100 mg caplet by mouth twice per day for 12 months. Total dose per day 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alagebrium (generic: ALT-711)
Description: The dosage of our drug, ALT-711, will be one 100 mg caplet by mouth twice per day for 12 months. Total dose per day 200 mg.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi and/or Yoga Training
Description: Tai Chi or Yoga training includes a series of exercises that improve flexibility, balance and coordination. Training will be supervised by trained instructors. This training will occur 3 times per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi and/or Yoga Training
Description: Tai Chi or Yoga training includes a series of exercises that improve flexibility, balance and coordination. Training will be supervised by trained instructors. This training will occur 3 times per week.
Study: NCT01437111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet
Description: One combination tablet orally once a week
Study: NCT04428255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9161 Dose A
Description: HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9161 Dose B
Description: HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
Study: NCT05009173

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar puncture using the stylet-in technique
Description: This method consists of inserting the needle with the stylet-in, then only remove the stylet once the desired depth is achieved and CSF flow is expected. If no CSF comes back, the stylet is replaced before continuing to advance the needle until the subarachnoid space is entered. This is the technique generally used in our emergency department and will serve as the control treatment group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar puncture using the stylet-out technique
Description: This method consists of inserting the needle through the epidermis and the dermis, which is estimated as a 0.5 to 1 cm length in children, then remove the stylet before progressing through the other structures until the subarachnoid space is entered. This approach will be used in the experimental technique group.
Study: NCT00738569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 mg PO BID for 12 months
Study: NCT01110525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: 4X100 mg per oral, twice daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neovletta 21/28
Description: Once daily with (21) or without (28) pause for bleeding.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neovletta 21/28
Description: Once daily with (21) or without (28) pause for bleeding.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo AZD1981
Description: 4X100 mg per oral, twice daily for 28 days
Study: NCT01307046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to MK-0954A
Description: Placebo tablet to match MK-0954A, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to losartan 100 mg
Description: Placebo tablet to match losartan 100 mg, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to losartan 50 mg
Description: Placebo tablet to match losartan 50 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to losartan 50 mg
Description: Placebo tablet to match losartan 50 mg, once daily
Study: NCT01432938

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dulaglutide
Description: Administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dulaglutide
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Administered orally
Study: NCT00801710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BridgePoint Medical System (CrossBoss Catheter, Stingray Catheter, Entera Guidewire)
Description: Revascularization of coronary artery chronic total occlusion.~Use of the BridgePoint Medical System to cross coronary CTOs prior to definitive revascularization treatment via angioplasty and/or stent implant
Study: NCT01128452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVT 101
Description: HPMC Capsule, 15 mg, once daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: HPMC Placebo capsules, once daily for 28 days
Study: NCT03285490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX2-391 Ointment 1%
Description: Dose: 1% (250 mg single-use packets); Dosage form: Ointment; Route of administration: Topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage form: Ointment; Route of administration: Topical
Study: NCT03052465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test soup meal feeding intervention
Description: Cream of chicken soup (400g) (or mushroom for vegetarians) (Heinz, Wigan, UK) used as a test meal intervention. The nutrient content /100g is: energy (kcal) 51, protein (g) 1.5, carbohydrate (g) 4.7, fat (g) 2.93
Study: NCT01897259

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: Participants in the placebo group will recieve placebo injections (1cc 1% lidocaine and 1cc normal saline).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Subjects participating in the physical therapy group will attend physical therapy and be prescribed to NSAIDS. No prolotherapy or corticosteroid injections.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injections
Description: Participants in the corticosteroid group will recieve corticosteroid injections (1 cc Kenalog 10 mg). They will also recieve anesthetic of 1 ml 1% lidocaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolotherapy
Description: Subjects participating in the prolotherapy group will recieve 1 cc 50% Dextrose and Sodium Morrhuate 1 cc injections.
Study: NCT03273699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Clients will use a consumer grade EEG device that provides guided mindfulness home practices
Study: NCT04174872

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: it has a sedative effect without significant respiratory depression , anxiolytic, analgesic, antihypertensive and sympatholytic properties. It is now being used as a neuraxial adjuvant that can be used as an effective adjuvant in epidural anaesthesia as it intensifys the motor block and prolongs the duration of postoperative analgesia.

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: it has a sedative effect without significant respiratory depression , anxiolytic, analgesic, antihypertensive and sympatholytic properties. It is now being used as a neuraxial adjuvant that can be used as an effective adjuvant in epidural anaesthesia as it intensifys the motor block and prolongs the duration of postoperative analgesia.

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Midazolam has been reported to have a spinally mediated analgesic effect. Clinically, single-shot epidural or spinal administration of midazolam has been shown to have an analgesic effect on perioperative pain.

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Midazolam has been reported to have a spinally mediated analgesic effect. Clinically, single-shot epidural or spinal administration of midazolam has been shown to have an analgesic effect on perioperative pain.
Study: NCT03898323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcohol Approach Bias Modification
Description: Computerized training
Study: NCT01040728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI1744) Low
Description: Low dose inhaled orally once daily from Respimat inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI1744) High
Description: High dose inhaled orally once daily from Respimat inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18 mcg
Description: 18 mcg inhaled once daily from HandiHaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Olodaterol (BI1744)l)
Description: Placebo (olodaterol low and high dose) delivered by Respimat

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Tiotropium)
Description: Placebo (Tiotropium 18 mcg) delivered by HandiHaler
Study: NCT02333136

Intervention type: DEVICE
Intervention: raman spectroscopy (LighTouch)
Description: near infrared light will be shone upon a fingerbed capillary and light scatter measured using in vivo raman spectroscpy
Study: NCT00394654

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-528 9 mg/kg
Description: MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as a single intravenous infusion
Study: NCT03253185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-007
Description: intravenous
Study: NCT02941042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC9204-1177
Description: A single dose administered subcutaneously ( s.c. under the skin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose administered subcutaneously ( s.c. under the skin)
Study: NCT02936115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TruSkin®

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound Cover
Study: NCT00909194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Seminar and Relaxation Technique
Description: Psychoeducational seminar on Juvenile Primary Fibromyalgia (pain management, diet, exercise and sleep hygiene) followed by a total body relaxation technique
Study: NCT03044743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: To modify immune micro-environment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: To modify immune micro-environment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: To sustain the survival of infused T cells
Study: NCT02628899

Intervention type: DEVICE
Group type: OTHER
Intervention: Transfemoral TAVR

Intervention type: DEVICE
Group type: OTHER
Intervention: Transfemoral TAVR

Intervention type: DEVICE
Group type: OTHER
Intervention: SAVR
Study: NCT03178175

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: In the acupuncture with De Qi group, using stainless tiny needles is inserted to the specific acupoints over the scalp (Si Shen Cong and Baihui) until the De Qi phenomenon occurs. The duration is about 30 minutes, and all patients will receive the procedure 16 times within 2 months.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Needle Insertion
Description: In the Sham acupuncture group, using stainless tiny needles is inserted to the specific acupoints over the scalp (Si Shen Cong and Baihui) but the needle doesn't reach the exact depth and De Qi phenomena doesn't occur. The duration is about 30 minutes, and all patients will receive this procedure 16 times within 2 months.
Study: NCT01327573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eculizumab
Description: * Eculizumab Induction 600mg IV every 7 days for 4 doses~* Eculizumab 900mg IV 7 days later~* Eculizumab Maintenance 900mg IV every 14 days for total of 26 weeks